| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,825 | 3,661 | ||
| General and administrative | 4,049 | 3,630 | ||
| Total operating expenses | 6,874 | 7,291 | ||
| Loss from operations | -6,874 | -7,291 | ||
| Other income, net | 263 | 325 | ||
| Net loss | -6,611 | -6,966 | ||
| Unrealized (loss) gain on available-for-sale securities | 1 | 1 | ||
| Comprehensive loss attributable to common stockholders | -6,610 | -6,965 | ||
| Earnings per share, basic | -1.68 | -0.18 | ||
| Earnings per share, diluted | -1.68 | -0.18 | ||
| Weighted average number of shares outstanding, basic | 3,943,887 | 39,092,961 | ||
| Weighted average number of shares outstanding, diluted | 3,943,887 | 39,092,961 | ||
Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. (ATHA)